Introduction of Prescription Oral Antivirals for COVID-19 to the Commercial Market
Customize your policy alerts
Sign up for all globalhealth policy alerts
Know when globalhealth releases new policies or updates existing guidance.
Monitor payer policy activity
Guidance for Medicare Part D sponsors on formulary inclusion, claims processing, and reporting for commercial and USG-distributed oral antivirals (Paxlovid and Lagevrio) as they transition to the commercial market; affects Part D sponsors, pharmacies, and Medicare beneficiaries.
Guidance expanding prior November 4, 2022 memorandum to address transition of oral antivirals to the commercial market and dual supplies (USG-distributed and commercial).
Commercial Paxlovid is available through a patient assistance program (USG PAP) allowing $0 cost sharing for beneficiaries through December 31, 2024, including a Part D plan-facilitated pathway and a standalone Pfizer-operated pathway.
CMS will reject PDEs for EUA-labeled Paxlovid with dates of service after March 8, 2024.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.